Form 4: TherapeuticsMD Director Collins Buys 1,200 Shares of TXMD

Director Cooper C. Collins of TherapeuticsMD, Inc. (TXMD) purchased 1,200 shares of common stock at an average price of $1.6988 on August 21, 2024.

Summary

• On August 21, 2024, Cooper C. Collins, a director of TherapeuticsMD, Inc. (TXMD), acquired 1,200 shares of the company's common stock.
• The shares were purchased at a weighted average price of $1.6988.
• The transactions occurred at prices ranging from $1.685 to $1.70.
• Following the reported transaction, Collins directly owns 47,922 shares of TherapeuticsMD.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director buying shares is generally a good sign, but the purchase is relatively small.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, but should be considered alongside other factors.

Stakeholder Impact

• The purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

TherapeuticsMD, TXMD, Director, Insider Trading, Stock Purchase, Cooper Collins, Form 4